Logo
  • Home
  • AI Agent
  • Annotations
  • Watchlists
  • Files
  • Pricing and plans
  • BlogAboutContact us
    APIMCP
    Terms of servicePrivacy policy

  • Get the full experience

    We save the real magic for signed-in users.

Logo
NVO US​

Novo Nordisk A/S(NVO US)

$39.05-0.380.96%Ext:$39.04-0.010.02%(Market Closed · 23:55:47 UTC)

Overview

ProfileEntity Structure

Documents

SEC Filings
EDINET Filings

Financials & Metrics

FinancialsChartingShort InterestEmployees

Novo Nordisk A/S — Company Profile

Novo Nordisk A/S operates as a prominent global pharmaceutical firm, dedicated to the discovery, development, production, and distribution of a wide array of medicinal products. Its extensive operations are primarily structured into two distinct divisions: Diabetes and Obesity Care, and Biopharmaceuticals. The Diabetes and Obesity Care segment offers comprehensive solutions, encompassing various insulin preparations, GLP-1 receptor agonists along with their delivery systems, oral antidiabetic medications, treatments for weight management, and therapies addressing other chronic health conditions. Meanwhile, the Biopharmaceuticals division is focused on specialized treatments for hemophilia, growth hormone disorders, and hormone replacement therapy. The company actively engages in strategic collaborations, notably including an agreement with Gilead Sciences, Inc. Furthermore, Novo Nordisk A/S is engaged in a research partnership with Lumen Bioscience, Inc., aiming to explore innovative methods for administering oral biologics for the management of cardiometabolic diseases. Established in 1923, the company's main corporate offices are located in Bagsvaerd, Denmark.

Sector
Health Care
Industry
Pharmaceuticals
Exchange
UN
CEO
Maziar Mike Doustdar
Headquarters
Bagsvaerd, G7, DK
IPO Date
Apr 30, 1981
Employees
68,794
Website
www.novonordisk.com

Key Metrics

Price
$37.32
Market Cap
$165.72B
Revenue (TTM)
$96.82B
Net Income (TTM)
$48.56B
EPS (TTM)
10.93
P/E (TTM)
1.36
P/B (TTM)
0.82
Dividend Yield
5.11%
ROE (TTM)
23.91%
ROA (TTM)
8.68%
Operating Margin
61.57%
Beta
0.92

Dividends

Last Dividend
$1.22
Last Yield
0.05%

Summary

Novo Nordisk A/S operates as a prominent global pharmaceutical firm, dedicated to the discovery, development, production, and distribution of a wide array of medicinal products. Its extensive operations are primarily structured into two distinct divisions: Diabetes and Obesity Care, and Biopharmaceuticals. The Diabetes and Obesity Care segment offers comprehensive solutions, encompassing various insulin preparations, GLP-1 receptor agonists along with their delivery systems, oral antidiabetic medications, treatments for weight management, and therapies addressing other chronic health conditions. Meanwhile, the Biopharmaceuticals division is focused on specialized treatments for hemophilia, growth hormone disorders, and hormone replacement therapy. The company actively engages in strategic collaborations, notably including an agreement with Gilead Sciences, Inc. Furthermore, Novo Nordisk A/S is engaged in a research partnership with Lumen Bioscience, Inc., aiming to explore innovative methods for administering oral biologics for the management of cardiometabolic diseases. Established in 1923, the company's main corporate offices are located in Bagsvaerd, Denmark.

Website
www.novonordisk.com
Location
Bagsvaerd, G7, DK
Phone45 44 44 88 88
Employees68,794
CEOMaziar Mike Doustdar
Sector
Health Care
Industry
Pharmaceuticals
IPO DateApr 30, 1981

Ask AI

Company overview
Business model, segments, and competition.
Peer comparison
Metrics vs closest competitors.
Guidance & outlook
Forward guidance and assumptions.
Bull vs bear case
Upside drivers and key risks.
Valuation snapshot
Multiples vs history and peers.
Competitive moat
Defensibility and market position.
Management track record
Leadership and capital allocation history.

Latest Documents

SEC Filings(2K)

Expand
  • 6-KCurrent report (foreign private issuer)19 Oct
  • 6-KCurrent report (foreign private issuer)13 Oct
  • 6-KCurrent report (foreign private issuer)6 Oct
  • 6-KCurrent report (foreign private issuer)2 Oct
  • 6-KCurrent report (foreign private issuer)28 Sep
  • 6-KCurrent report (foreign private issuer)21 Sep
  • 6-KCurrent report (foreign private issuer)17 Sep
  • 6-KCurrent report (foreign private issuer)15 Sep
  • 6-KCurrent report (foreign private issuer)9 Sep
  • 6-KCurrent report (foreign private issuer)31 Aug
  • 6-KCurrent report (foreign private issuer)24 Aug
  • 6-KCurrent report (foreign private issuer)18 Aug
  • 6-KCurrent report (foreign private issuer)10 Aug
  • 6-KCurrent report (foreign private issuer)10 Aug
  • 6-KCurrent report (foreign private issuer)4 Aug
  • 6-KCurrent report (foreign private issuer)4 Aug
  • 6-KCurrent report (foreign private issuer)4 Aug
  • 6-KCurrent report (foreign private issuer)31 Jul
  • 6-KCurrent report (foreign private issuer)27 Jul
  • 6-KCurrent report (foreign private issuer)21 Jul

EDINET Filings(15)

Expand
  • 10-KAnnual Securities Report (2025.01.01-2025.12.31)30 Apr
  • IRSemi-Annual Report (2025.01.01-2025.12.31)29 Sep 2025
  • 10-KAnnual Securities Report (2024.01.01-2024.12.31)29 Apr 2025
  • IRAmended semi-annual report29 Nov 2024
  • IRSemi-Annual Report (2024.01.01-2024.12.31)30 Sep 2024
  • 10-KAmended Annual Securities Report13 Jun 2024
  • 10-KAnnual Securities Report (2023.01.01-2023.12.31)30 Apr 2024
  • 10-KAnnual Securities Report (2021.01.01-2021.12.31)28 Apr 2022
  • 10-KAmended Annual Securities Report20 May 2021
  • 10-KAnnual Securities Report (2020.01.01-2020.12.31)30 Apr 2021
  • 10-KAnnual Securities Report (2019.01.01-2019.12.31)28 Apr 2020
  • 10-KAnnual Securities Report (2018.01.01-2018.12.31)24 Apr 2019
  • 10-KAnnual Securities Report (2017.01.01-2017.12.31)26 Apr 2018
  • 10-KAnnual Securities Report (2016.01.01-2016.12.31)28 Apr 2017
  • 10-KAnnual Securities Report (2015.01.01-2015.12.31)28 Apr 2016

News

  • NVO vs. VKTX: Which Obesity Stock Could Deliver Bigger Gains?22 Oct
  • Bristol Myers Squibb vs. Novo Nordisk: Stable Scale vs.22 Oct
  • 48,696 Novo Nordisk A/S $NVO Shares Sold by Carnegie Investment Counsel22 Oct
  • Where Will Novo Stock Be in 10 Years?21 Oct
  • How Will Novo's GLP-1 Portfolio Sales Aid Upcoming Q3 Results?21 Oct
  • Obesity ETFs to Gain as Novo's CagriSema Shows 25% Weight Loss21 Oct
  • Novo's CagriSema Delivered 25% Weight Loss in Women. Could It Help Turn Around the Beaten-Down Stock?21 Oct
  • Eli Lilly Rises 4% While Foundayo Nears European Approval; Amgen and Novo Nordisk Edge Higher20 Oct
  • Novo Nordisk stock rises as CagriSema delivers 25% weight loss in women20 Oct
  • Novo's next-generation obesity drug shows 25% weight loss in women in late-stage analysis20 Oct
  • Novo Nordisk (NVO) Stock Sinks As Market Gains: Here's Why19 Oct
  • Is Trending Stock Novo Nordisk A/S (NVO) a Buy Now?19 Oct
  • Novo Nordisk A/S - share repurchase programme19 Oct
  • Novo Trades at Less Than 12 Times Earnings. Is This the Buying Opportunity of the Decade?18 Oct
  • Novo Nordisk and Eli Lilly Just Got Some Fantastic News16 Oct
  • Why Novo Nordisk (NVO) Dipped More Than Broader Market Today13 Oct
  • AbbVie vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026?13 Oct
  • Novo Down 11% in a Month: How Should Investors Approach the Stock Now?12 Oct
  • Bristol Myers Squibb vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026?10 Oct
  • UBS Called Novo Nordisk a 'Value Trap.' Here's the Other Side of That Argument.8 Oct

Mentions in Filings

  • … Ventus Therapeutics, Inc., a biopharmaceutical company, since November 2021. Ms. Henderson previously served as a member of the board of directors of Akero Therapeutics, Inc., a biopharmaceutical company (acquired by <strong>Novo Nordisk A/S</strong>), from April 2019 to December 2025; Cargo Therapeutics, Inc. (acquired by Concentra Biosciences, LLC), a biotechnology company, from June 2024 to August 2025; IVERIC bio, Inc. (acquired by Astellas Pharma Inc.), a bi …
    Lycia Therapeutics, Inc.Novo Nordisk A/S·424B4 - Prospectus filing (Rule 424(b)(4))·Q4 26·23 Oct
  • … armaceuticals, Inc. Our Chief Medical Officer, Jyothis George, MBBS, Ph.D., brings substantial drug development experience, having held senior clinical, medical and regulatory roles at companies including Amgen Inc., <strong>Novo Nordisk A/S</strong>, or Novo Nordisk, and Boehringer Ingelheim Pharmaceuticals, Inc. Our founder and Chief Scientific Officer, Alan P. Watt, Ph.D., M.B.A., brings substantial research, discovery, nonclinical and translational experience …
    Rezera Inc.Novo Nordisk A/S·S-1 - Registration statement (general form)·Q4 26·21 Oct
  • … Ventus Therapeutics, Inc., a biopharmaceutical company, since November 2021. Ms. Henderson previously served as a member of the board of directors of Akero Therapeutics, Inc., a biopharmaceutical company (acquired by <strong>Novo Nordisk A/S</strong>), from April 2019 to December 2025; Cargo Therapeutics, Inc. (acquired by Concentra Biosciences, LLC), a biotechnology company, from June 2024 to August 2025; IVERIC bio, Inc. (acquired by Astellas Pharma Inc.), a bi …
    Lycia Therapeutics, Inc.Novo Nordisk A/S·S-1/A - Registration statement (general form, amendment)·Q4 26·20 Oct
  • … o Biopharmaceutical Co., Ltd., Aro Biotherapeutics Co., Arrowhead Pharmaceuticals, Inc., AstraZeneca plc, Dyne Therapeutics, Inc., Eli Lilly and Company, GlaxoSmithKline plc, Ionis Pharmaceuticals, Inc., Novartis AG, <strong>Novo Nordisk A/S</strong>, SanegeneBio Inc., Sarepta Therapeutics, Inc., Silence Therapeutics plc, and Sirius Therapeutics, Inc. Our competitors have developed, are developing or may develop product candidates and products competitive with C …
    CITY THERAPEUTICS, INC.Novo Nordisk A/S·424B4 - Prospectus filing (Rule 424(b)(4))·Q4 26·16 Oct
  • … cretin tablet formulation (“ALT 2 DHT3.0 Tablet”), rendered in a 4 mg oral tablet format, evidenced a 136%, or more than double, increase in *absolute bioavailability* (1.65%) compared to animal research published by <strong>Novo Nordisk A/S</strong> that indicated an absolute bioavailability level of 0.70% for its SNAC-inclusive orally administered amycretin at comparable dosing, but without DHT, in primates. In addition, the results indicated that the 3 various …
    Lexaria Bioscience Corp.Novo Nordisk A/S·424B3 - 424 B3·Q1 27·13 Oct
  • … o Biopharmaceutical Co., Ltd., Aro Biotherapeutics Co., Arrowhead Pharmaceuticals, Inc., AstraZeneca plc, Dyne Therapeutics, Inc., Eli Lilly and Company, GlaxoSmithKline plc, Ionis Pharmaceuticals, Inc., Novartis AG, <strong>Novo Nordisk A/S</strong>, SanegeneBio Inc., Sarepta Therapeutics, Inc., Silence Therapeutics plc, and Sirius Therapeutics, Inc. Many of our competitors have: 29 Table of Contents • substantially greater financial, technical and human res …
    CITY THERAPEUTICS, INC.Novo Nordisk A/S·S-1/A - Registration statement (general form, amendment)·Q4 26·9 Oct

Key Stats

Trading

Px/Chg 1D$37.32 / -0.21%
Avg Volume18.12M
Beta0.92
Mkt Cap165.72B
FD Mkt Cap201.58B

Float

Shrs Out/Float4.44B / 3.17B
Short Float0.01%
Days to Cover2.20
Stock Repurchased$2.40B

Current Valuation

EV290.98B
EV/EBITDA1.57
EV/Sales0.89
P/B0.82
P/S0.51
FCF Yield7.27%
ROE23.91%
ROA8.68%
Current Ratio0.79

Dividend

Cash$1.22
Yield5.11%
Yield (TTM)5.11%

Estimates

P/E1.36
Est P/EN/A
Est EPSN/A
Est PEGN/A

Valuation

Metric5Yr AvgMar '23Mar '24May '25May '26Oct '26
PRICE-BASED RATIOS
Price / Earnings5.426.456.882.927.423.41
Price / Sales1.952.022.481.022.521.71
Price / Book Value2.724.295.402.061.030.82
Price / Free Cash Flow5.265.588.224.24-5.5113.76
ENTERPRISE VALUE METRICS
Enterprise Value387,381.8371,274.9588,205.5382,381.0304,069.1290,978.5
Enterprise Value / Sales2.562.102.531.323.843.01
Enterprise Value / EBITDA4.884.835.132.587.654.20
Enterprise Value / EBIT5.455.355.592.978.894.43

Financials

Full Financials
Millions DKK5Yr CAGR (%)Dec '21Dec '22Dec '23Dec '24Dec '25
INCOME STATEMENT
Revenue21.7%140,800.0176,954.0232,261.0290,403.0309,064.0
Gross Income20.9%117,142.0148,506.0196,496.0245,881.0250,276.0
EBITDA24.4%65,394.076,802.0114,629.0147,938.0156,729.0
EBIT22.7%59,369.069,440.0105,216.0128,831.0134,747.0
Net Income21%47,757.055,525.083,683.0100,988.0102,434.0
EPS (Diluted)22.1%10.3712.2218.6222.6323.03
BALANCE SHEET
Cash & ST Inv11.4%17,485.023,574.030,230.026,308.026,962.0
Total Assets29.3%194,508.0241,257.0314,486.0465,795.0542,902.0
Total Liabilities29.6%123,762.0157,771.0207,925.0322,309.0348,855.0
Total Shareholder Equity28.7%70,746.083,486.0106,561.0143,486.0194,047.0
CASH FLOW
Net Operating Cash Flow21.3%55,000.078,887.0108,908.0120,968.0119,102.0
Cap Ex86.9%-7,385.0-14,753.0-38,896.0-51,309.0-90,113.0
Free Cash Flow-11.7%47,615.064,134.070,012.069,659.028,989.0

Enterprise Value Bridge

Millions DKK23 Oct '26
Price (As of 23 Oct '26)38.95
Basic Shares4,440.61
Market Cap172,939.5
Diluted Shares4,448.70
Fully Diluted Shares Outstanding4,448.70
Fully Diluted Market Cap173,254.6
+Consolidated Debt146,382.0
−In-the-Money Convertible Debt—
+Capital Leases-
+Operating Leases—
−Cash & Equivalents-21,127.0
−Short-term Investments-499.0
+Total Preferred-
−In-the-Money Convertible Preferred—
−Investments in Unconsolidated Subs—
+Non-Controlling Interest-
+Pension Liabilities—
Enterprise Value298,194.5

Segment data

Revenue

by Geography

  • North America63%
  • Emea24%
  • Rest Of World13%

Related companies

Eli Lilly and Company

LLY US

Johnson & Johnson

JNJ US

AbbVie Inc.

ABBV US

Merck & Co., Inc.

MRK US

Novartis Ag

NVS US

Astrazeneca Plc

AZN US

Abbott Laboratories

ABT US

Pfizer Inc

PFE US

Vertex Pharmaceuticals Inc / Ma

VRTX US

Bristol Myers Squibb Company

BMY US

Csl Ltd

CSLLY US

Sanofi

SNY US